Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.90 USD
Change Today +0.03 / 0.44%
Volume 136.7K
LBIO On Other Exchanges
Symbol
Exchange
Stuttgart
As of 3:35 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

lion biotechnologies inc (LBIO) Snapshot

Open
$6.75
Previous Close
$6.87
Day High
$6.98
Day Low
$6.71
52 Week High
03/20/15 - $15.03
52 Week Low
11/18/14 - $4.97
Market Cap
325.6M
Average Volume 10 Days
278.7K
EPS TTM
$-0.56
Shares Outstanding
47.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LION BIOTECHNOLOGIES INC (LBIO)

Related News

No related news articles were found.

lion biotechnologies inc (LBIO) Related Businessweek News

No Related Businessweek News Found

lion biotechnologies inc (LBIO) Details

Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company’s lead product includes LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors for the treatment of patients with refractory metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. to manufacture, package, ship, and perform quality assurance and quality control of TIL therapy. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in Woodland Hills, California.

14 Employees
Last Reported Date: 03/16/15
Founded in 2007

lion biotechnologies inc (LBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $336.9K
Vice President of Manufacturing
Total Annual Compensation: $290.2K
Chief Scientific Officer
Total Annual Compensation: $187.2K
Compensation as of Fiscal Year 2014.

lion biotechnologies inc (LBIO) Key Developments

Lion Biotechnologies, Inc. Announces Executive Appointments

Lion Biotechnologies, Inc. announced the appointments of Gregory MacMichael, PhD, as vice president of process development, and Howard B. Johnson as vice president of corporate development. Dr. MacMichael joins the company from Novartis' Cell and Gene Therapies Therapeutic Unit, where he led process development for CAR-T and other immunotherapies. Previously, he led the development of the drug substance and drug product processes for Novartis' biologics pipeline. With more than 30 years of experience in drug product development, Dr. MacMichael has held senior process development and R&D positions at several leading biopharmaceutical companies. Mr. Johnson is an entrepreneurial executive with more than 30 years of experience in operations, finance, business development and investor relations, primarily in healthcare companies. Most recently, he co-founded GO4HLTH, and served as CEO of VentriNova.

Lion Biotechnologies, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Lion Biotechnologies, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company has posted loss from operations was $6,440,000 against $2,110,000 a year ago. Net loss was $6,367,000 or $0.14 basic and diluted per share against $2,110,000 or $0.09 basic and diluted per share a year ago. For the six months, the company has posted loss from operations was $11,739,000 against $4,370,000 a year ago. Net loss was $11,666,000 or $0.28 basic and diluted per share against $4,370,000 or $0.19 basic and diluted per share a year ago.

Lion Biotechnologies, Inc.(NasdaqGM:LBIO) added to Russell 2000 Index

Lion Biotechnologies, Inc. will be added to Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LBIO:US $6.90 USD +0.03

LBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LBIO.
View Industry Companies
 

Industry Analysis

LBIO

Industry Average

Valuation LBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LION BIOTECHNOLOGIES INC, please visit www.genesis-biopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.